1 – 28 of 28
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Breast cancer associated CD169+ macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells
(
- Contribution to journal › Article
-
Mark
Patient-derived models : Advanced tools for precision medicine in neuroblastoma
(
- Contribution to journal › Article
-
Mark
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
(
- Contribution to journal › Article
- 2022
-
Mark
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance
(
- Contribution to journal › Article
- 2021
-
Mark
Label-free separation of neuroblastoma patient-derived xenograft (PDX) cells from hematopoietic progenitor cell products by acoustophoresis
(
- Contribution to journal › Article
-
Mark
Anti-tumor effects of rigosertib in high-risk neuroblastoma
(
- Contribution to journal › Article
-
Mark
Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma
(
- Contribution to journal › Article
- 2020
-
Mark
Integrative discovery of treatments for high-risk neuroblastoma
(
- Contribution to journal › Article
-
Mark
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
(
- Contribution to journal › Article
-
Mark
Discovery of epi-enprioline as a novel drug for the treatment of vincristine resistant neuroblastoma
(
- Contribution to journal › Article
-
Mark
Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer
(
- Contribution to journal › Article
-
Mark
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma
(
- Contribution to journal › Article
-
Mark
Inflammatory macrophage derived TNFα downregulates estrogen receptor α via FOXO3a inactivation in human breast cancer cells
(
- Contribution to journal › Article
- 2019
-
Mark
Multidimensional intratumour heterogeneity in neuroblastoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
ALK positively regulates MYCN activity through repression of HBP1 expression
(
- Contribution to journal › Article
-
Mark
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma
(
- Contribution to journal › Article
- 2018
-
Mark
Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma
(
- Contribution to journal › Article
-
Mark
Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer
(
- Contribution to journal › Article
-
Mark
Patient-derived xenografts as preclinical neuroblastoma models
(
- Contribution to journal › Article
- 2017
-
Mark
Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum
(
- Contribution to journal › Article
- 2016
-
Mark
Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers
(
- Contribution to journal › Article
-
Mark
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
(
- Contribution to journal › Scientific review
-
Mark
Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours
(
- Contribution to journal › Article
- 2015
-
Mark
Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.
(
- Contribution to journal › Article
-
Mark
PI3K-mTORC2 but not PI3K-mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma.
(
- Contribution to journal › Article
-
Mark
Neuroblastoma Patient-Derived Orthotopic Xenografts Retain Metastatic Patterns and Geno- and Phenotypes of Patient Tumours.
(
- Contribution to journal › Article
- 2013
-
Mark
Stem cell-based therapy for malignant glioma.
(
- Contribution to journal › Scientific review
- 2009
-
Mark
CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
(
- Contribution to journal › Article